Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?
Stockholm University, Faculty of Science, Department of Biochemistry and Biophysics.ORCID iD: 0000-0001-7472-0439
Number of Authors: 12023 (English)In: Frontiers in Endocrinology, E-ISSN 1664-2392, Vol. 13, article id 1057749Article, review/survey (Refereed) Published
Abstract [en]

The hypothalamic neuroendocrine catecholamine dopamine regulates the lactotroph function, including prolactin (PRL) secretion, proliferation, and apoptosis. The treatment of PRL-secreting tumors, formerly known as prolactinomas, has relied mainly on this physiological characteristic, making dopamine agonists the first therapeutic alternative. Nevertheless, the group of patients that do not respond to this treatment has few therapeutical options. Prolactin is another physiological regulator of lactotroph function, acting as an autocrine/paracrine factor that controls PRL secretion and cellular turnover, inducing apoptosis and decreasing proliferation. Furthermore, the signaling pathways related to these effects, mainly JAK/STAT and PI3K/Akt, and MAPK, have been extensively studied in prolactinomas and other tumors as therapeutic targets. In the present work, the relationship between PRL pathophysiology and prolactinoma development is explored, aiming to comprehend the value of PRL and PRLR-associated pathways as exploratory fields alternative to dopamine-related approaches, which are worth physiological characteristics that might be impaired and can be potentially restored or upregulated to provide more options to the patients.

Place, publisher, year, edition, pages
2023. Vol. 13, article id 1057749
Keywords [en]
prolactinomas, PRL, PiNETs, PRL receptor, JAK/STAT, PI3K/AKT
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:su:diva-214799DOI: 10.3389/fendo.2022.1057749ISI: 000918412000001PubMedID: 36714572Scopus ID: 2-s2.0-85146972819OAI: oai:DiVA.org:su-214799DiVA, id: diva2:1737268
Available from: 2023-02-16 Created: 2023-02-16 Last updated: 2024-01-17Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Ferraris, Jimena

Search in DiVA

By author/editor
Ferraris, Jimena
By organisation
Department of Biochemistry and Biophysics
In the same journal
Frontiers in Endocrinology
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 6 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf